Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

A significant breakthrough in treating the Human Immunodeficiency Virus came recently with the US Federal Drug Administration approving lenacapavir, a new prototype medication. It uses a unique ...

NEW DELHI: In a major step forward in the fight against HIV/AIDS, the US Food and Drug Administration (FDA) has approved Lenacapavir, an injectable HIV drug. This drug protects people for six ...

GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Morgan Stanley has upgraded Gilead Sciences (GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. Read more here.

Every year, the high-profile academic journal "Science" names ten groundbreaking discoveries in a top list of scientific ...

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

Researchers at the Max Planck Institute of Biophysics and Heidelberg University have observed largely intact HIV-1 capsids as ...